Suzhou Basecare Medical Corp. Ltd. reported its interim results for the six months ended June 30, 2025. Revenue for the period was RMB101.3 million, representing a decrease of 18.8% compared to RMB124.7 million in the same period last year. The company's net assets decreased to RMB1,031.7 million from RMB1,141.8 million as of the previous period. During the reporting period, Suzhou Basecare generated revenue from the sales of testing kits, testing and cryopreservation devices and instruments, embryo culture devices, embryo culture solution, consumables, and other products. The company stated that it continues to focus on developing AI-driven innovations in assisted reproduction, including the advancement of its "AI+Reproduction" platform and the iARMS intelligent management system. Suzhou Basecare plans to accelerate global promotion of new products and enhance penetration in the domestic market, supported by international brand partnerships and the local healthcare policy environment. The company will leverage AI to upgrade laboratory scenarios across genetics, andrology, embryos, and cryopreservation, aiming to drive competitiveness and growth in both domestic and international markets.